A phase II study of Bevacizumab plus Docetaxel for advanced large cell neuroendocrine carcinoma (LCNEC) with previously treated with platinum based chemotherapy
Phase 2
Recruiting
- Conditions
- arge cell neuroendocrine carcinoma (LCNEC)
- Registration Number
- JPRN-UMIN000011713
- Lead Sponsor
- Toho University Omori Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
Severe or uncontrollable systemic disease 2) Active infection 3) Active concomitant malignancy 4) Symptomatic brain metastasis 5) Uncontrollable pleural effusion, ascites, or pericardial effusion 6) History of GI perforation 7) Tendency to hemorrhages 8) Pregnancy, breast feeding and suspected pregnancy 9) Invasion to major vessel or cavitations of tumor 10) Uncontrollable hypertension 11) Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Overall survival Safety Progression free survival